UroGen Pharma (NASDAQ: URGN) revenue
UroGen Pharma reported revenue of $109.8m for fiscal 2025, 21.4% more than in fiscal 2024 ($90.4m). Since fiscal 2016 its revenue has grown by 526.3%, an average growth of 22.6% a year.
UroGen Pharma has grown its revenue for 6 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2019, −98.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $109.8m | +21.4% | −$124.9m | −113.7% |
| 2024 | $90.4m | +9.3% | −$96.8m | −107.1% |
| 2023 | $82.7m | +28.5% | −$65.5m | −79.2% |
| 2022 | $64.4m | +34.0% | −$79.0m | −122.8% |
| 2021 | $48.0m | +307.2% | −$92.3m | −192.1% |
| 2020 | $11.8m | +65,450.0% | −$126.7m | −1,074.2% |
| 2019 | $0.0m | −98.4% | −$109.5m | −608,211.1% |
| 2018 | $1.1m | −86.2% | −$77.2m | −6,842.2% |
| 2017 | $8.2m | −53.5% | −$20.0m | −244.5% |
| 2016 | $17.5m | — | $0.8m | 4.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
UroGen Pharma revenue compared with its sector
By revenue for its latest fiscal year, UroGen Pharma ranks 280th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; UroGen Pharma, 21.4%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 278th | Immunitybio | $113.3m | 668.3% |
| 279th | Anika Therapeutics | $112.8m | −5.9% |
| 280th | UroGen Pharma | $109.8m | 21.4% |
| 281st | Century Therapeutics | $109.2m | 1,556.8% |
| 282nd | Zevra Therapeutics | $106.5m | 350.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of UroGen Pharma
- How much revenue did UroGen Pharma make in fiscal 2025?
- UroGen Pharma reported revenue of $109.8m for fiscal 2025, compared with $90.4m in fiscal 2024.
- How much has the revenue of UroGen Pharma grown?
- Between fiscal 2016 and fiscal 2025 it went from $17.5m to $109.8m: 526.3% more, an average growth of 22.6% a year.
- What was the best year for revenue at UroGen Pharma?
- Of its last 10 fiscal years, fiscal 2025, with $109.8m.
- Where does UroGen Pharma rank in its sector by revenue?
- It ranks 280th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for UroGen Pharma come from?
- From the annual report (Form 10-K) that UroGen Pharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that UroGen Pharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on UroGen Pharma: the UroGen Pharma page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.